Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn’s disease,Alimentary Pharmacology & Therapeutics

当前位置： X-MOL 学术 › Aliment. Pharm. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn’s disease
Alimentary Pharmacology & Therapeutics ( IF 7.6 ) Pub Date : 2021-12-22 , DOI: 10.1111/apt.16733
Ruben J Colman ₁ , Ye Xiong ₂ , Tomoyuki Mizuno _{2,

3} , Jeffrey S Hyams ₄ , Joshua D Noe ₅ , Brendan Boyle ₆ , Geert R D'Haens ₇ , Johan van Limbergen ₈ , Kelly Chun ₉ , Jane Yang ₉ , Michael J Rosen _{1,

3} , Lee A Denson _{1,

3} , Alexander A Vinks _{2,

3} , Phillip Minar _{1,

3}

Affiliation

Antibodies to infliximab (ATI) are associated with secondary loss of response and increased risk for drug reactions. Limited studies have associated ATI with increased infliximab clearance.

中文翻译：